Oral Anticholinergic Drops for Excessive Saliva
Start with an inexpensive oral anticholinergic medication as first-line therapy for sialorrhea, with sublingual atropine drops being the most effective oral anticholinergic option based on current evidence. 1
First-Line Treatment Approach
The 2023 American College of Chest Physicians guidelines explicitly recommend beginning with an inexpensive oral anticholinergic as initial therapy 1. While the guidelines don't specify which particular agent, they emphasize:
- Continue use only if benefits outweigh side effects
- Individual patient response varies significantly—some achieve symptomatic relief while others don't tolerate anticholinergics well
- The balance of risks and benefits is considered neutral due to this variability 1
Sublingual Atropine: The Superior Oral Anticholinergic
Sublingual atropine drops demonstrate superior efficacy compared to other routes of administration for reducing salivary flow 2. The evidence supporting this includes:
- Objective reduction in saliva secretion: A randomized placebo-controlled trial showed sublingual atropine (600 μg single dose) reduced saliva secretion by 57% compared to placebo (P = 0.02) 3
- Subjective improvement: Patients reported less saliva on pillows and better sleep quality 3
- Route superiority: Meta-analysis confirms sublingual administration is superior to oral tablets, subcutaneous, and intravenous routes 2
- Pediatric efficacy: Retrospective data shows statistically and clinically significant reductions in both drooling frequency and severity (median DFSS scores decreased from 4 to 3 for both parameters, P < 0.01) 4
Practical Dosing Considerations
While specific doses vary by study:
- Adults: 600 μg sublingual as studied in trials 3
- Pediatrics: Minimum 0.25 mg/kg once or twice daily based on PBPK modeling 5
Critical Caveats and Pitfalls
Acceptability Issues
Major concern: Off-label use of atropine eye drops administered sublingually (common practice in some regions) shows poor acceptability in real-world settings 6. Problems include:
- Lack of suitable administration device
- Bitter taste causing poor palatability
- Difficulty ensuring accurate dosing in patients with disabilities
- Atropine sublingual drops can be lethal in overdose 7—this is a critical safety consideration
Alternative Anticholinergics
If atropine is not tolerated or available:
- Glycopyrrolate (oral or subcutaneous formulations) can be considered as escalation therapy 1
- Glycopyrrolate doesn't cross the blood-brain barrier effectively, reducing delirium risk compared to other anticholinergics 8
- Anticholinergic patches offer longer-acting, more convenient alternatives after initial oral trials 1
When to Avoid Anticholinergics
- Patients with constipation risk (anticholinergics worsen this) 7
- Those unable to tolerate anticholinergic side effects (dry mouth, urinary retention, confusion)
- When side effects outweigh benefits—reassess regularly
Escalation Strategy When Anticholinergics Fail
If inadequate response or intolerance to anticholinergics occurs, escalate to botulinum toxin therapy to salivary glands 1. This provides:
- Weeks to months of benefit
- Simple, relatively comfortable injections
- Inexpensive option with mild-to-moderate adverse effects
Radiation therapy should be reserved for experienced centers and refractory cases due to irreversible dryness and unclear benefit-risk balance 1.
Clinical Context
Sialorrhea significantly reduces quality of life and increases risks of:
- Aspiration pneumonia
- Social embarrassment and isolation
- Skin breakdown around mouth
The condition is particularly common in neuromuscular diseases (especially ALS), cerebral palsy, Parkinson's disease, and as a side effect of clozapine 1, 7. Treatment is essential to prevent these morbidities.